In the fourth quarter of 2020, the first significant sales revenue was generated from the manufacture and delivery of Injection vials for Covid-19 vaccines<\/strong> were recorded. The company has significantly expanded its production capacity for the manufacture of injection vials.<\/p> \u201eThe successful acceleration of growth in large parts of our core business shows the effectiveness of our measures and gives us great confidence in our business development over the coming years. We continued to focus on the implementation of our strategy process in 2020. We are turning our Gerresheimer into a growth company as an innovation leader and solution provider.\u201c Dietmar Siemssen,<\/strong> CEO of Gerresheimer AG<\/p><\/blockquote>\n The aim is to accelerate sales growth in 2021 and achieve high single-digit growth rates in the medium term. \u201eWe want our shareholders to participate in our success. The Executive Board and Supervisory Board are proposing a dividend of EUR 1.25 per share for the 2020 financial year, the tenth consecutive increase.\u201c<\/p>\n In the fourth quarter, the Gerresheimer<\/a> AG achieved sales of 403 million euros. This corresponds to organic growth of 7.3 per cent in the core business. This consists of the Plastics & Devices and Primary Packaging Glass divisions.<\/p>![\"\"](\"https:\/\/packaging-journal.de\/wp-content\/uploads\/2026\/01\/PJ-Eigenwerbung-English-03.png\")
<\/a><\/div><\/div>\nGerresheimer with single-digit sales growth<\/h2>\n